EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Carrimycin suppresses the TCF3-BCR signaling axis and induces oxidative DNA damage in Burkitt lymphoma

Qingfeng Xue, Juan Ye, Herui Wang, Han Ye, Yaping Zhang, Shuran Chen, Zhengping Zhuang

Apoptosis · 2026-12 · 31 (12)

DOI: 10.1007/s10495-026-02477-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 11.11.2026. Verfasst von Qingfeng Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. xqfff1997@gmail.com. Hauptthemen laut MEDLINE: Signal Transduction, DNA Damage, Burkitt Lymphoma, Receptors, Antigen, B-Cell. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy with poor outcomes in relapsed or central nervous system (CNS)-involved cases. This study investigates the antitumor mechanism of Carrimycin, a genetically engineered macrolide antibiotic, in BL. In vitro assays demonstrated that Carrimycin exerts potent, dose-dependent cytotoxicity, inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis. Mechanistically, it triggered the generation of reactive oxygen species (ROS), leading to DNA damage. Transcriptomic profiling and molecular assays revealed that Carrimycin binds to the transcription factor 3 (TCF3), causing a collapse of the tonic B-cell receptor (BCR) signaling pathway. Genetic knockdown of TCF3 partially rescued BL cells from Carrimycin-induced cytotoxicity, confirming this molecular dependency. In vivo, Carrimycin suppressed tumor burden and prolonged survival in both subcutaneous and intracranial models with a favorable safety profile. In conclusion, Carrimycin is a therapeutic agent that targets TCF3 to inhibit the tonic BCR signaling axis while simultaneously driving lethal oxidative stress. Its systemic and intracranial efficacy positions Carrimycin as a highly promising candidate for clinical translation in high-risk and CNS-involved BL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionDNA DamageBurkitt LymphomaReceptors, Antigen, B-CellBasic Helix-Loop-Helix ProteinsHumansAnimalsReactive Oxygen SpeciesApoptosisCell Line, TumorOxidative StressMice

Stichwörter der Autor:innen

B-cell receptor signalingBurkitt lymphomaCarrimycinCentral nervous systemReactive oxygen speciesTranscription factor 3

Substanzen

Reactive Oxygen SpeciesTCF3 protein, humanReceptors, Antigen, B-CellBasic Helix-Loop-Helix Proteins

Autor:innen und Institutionen

  • Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. xqfff1997@gmail.com.
  • Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. zhengping.zhuang@nih.gov.

Förderung

  • Intramural NIH HHS
  • NCI

Zitieren

APA

Xue, Q., Ye, J., Wang, H., Ye, H., Zhang, Y., Chen, S., & Zhuang, Z. (2026). Carrimycin suppresses the TCF3-BCR signaling axis and induces oxidative DNA damage in Burkitt lymphoma. Apoptosis, 31(12). https://doi.org/10.1007/s10495-026-02477-x

Vancouver

Xue Q, Ye J, Wang H, Ye H, Zhang Y, Chen S, et al. Carrimycin suppresses the TCF3-BCR signaling axis and induces oxidative DNA damage in Burkitt lymphoma. Apoptosis. 2026;31(12). doi:10.1007/s10495-026-02477-x

BibTeX
@article{Xue2026,
  author = {Xue, Qingfeng and Ye, Juan and Wang, Herui and Ye, Han and Zhang, Yaping and Chen, Shuran and Zhuang, Zhengping},
  title = {Carrimycin suppresses the TCF3-BCR signaling axis and induces oxidative DNA damage in Burkitt lymphoma},
  journal = {Apoptosis},
  year = {2026},
  volume = {31},
  number = {12},
  doi = {10.1007/s10495-026-02477-x}
}
Kostenlos starten →